Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 5/20 | 0.72 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.72 |
| ▸ | MAPT | P10636 | 2/20 | 0.72 |
| ▸ | MEN1 | O00255 | 1/20 | 0.72 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.72 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.72 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.72 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.72 |
| ▸ | HTR2B | P41595 | 1/20 | 0.72 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.72 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.72 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.61 |
| ▸ | TSHR | P16473 | 3/20 | 0.61 |
| ▸ | TP53 | P04637 | 1/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.57 |
| ▸ | PTPN11 | Q06124 | 2/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8799353 | 1.00 | LMNA (0.72) | LMNACYP3A4MAPTMEN1NR1I2 | |
| SCHEMBL9245529 | 1.00 | LMNA (0.72) | LMNACYP3A4MAPTMEN1NR1I2 | |
| SCHEMBL7766053 | 0.93 | LMNA (0.62) | LMNACYP3A4MAPTMEN1NR1I2 | |
| SCHEMBL6709213 | 0.88 | LMNA (0.55) | LMNACYP3A4MAPTMEN1NR1I2 | |
| SCHEMBL15154872 | 0.87 | LMNA (0.77) | LMNACYP3A4MAPTMEN1NR1I2 | |
| SCHEMBL7078029 | 0.86 | ALDH1A1 (0.79) | LMNACYP3A4MAPTMEN1NR1I2 | |
| SCHEMBL6267333 | 0.86 | ALDH1A1 (0.79) | LMNACYP3A4MAPTMEN1NR1I2 | |
| SCHEMBL9636466 | 0.86 | ALDH1A1 (0.79) | LMNACYP3A4MAPTMEN1NR1I2 | |
| SCHEMBL2853795 | 0.86 | ALDH1A1 (0.79) | LMNACYP3A4MAPTMEN1NR1I2 | |
| SCHEMBL17961072 | 0.86 | ALDH1A1 (0.79) | LMNACYP3A4MAPTMEN1NR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190070113-A1 | Treating Ephrin Receptor A2 (Epha2) Positive Cancer with Targeted Docetaxel-Generating Nano-Liposome Compositions | MERRIMACK PHARMACEUTICALS, INC. (US) | 2019-03-07 | — | — | US | disclosed |
| EP-3429631-A1 | TREATING EPHRIN RECEPTOR A2 (EPHA2) POSITIVE CANCER WITH TARGETED DOCETAXEL-GENERATING NANO-LIPOSOME COMPOSITIONS | Merrimack Pharmaceuticals, Inc. (US) | 2019-01-23 | — | — | EP | disclosed |
| EP-3429629-A1 | EPHRIN RECEPTOR A2 (EPHA2)-TARGETED DOCETAXEL-GENERATING NANO-LIPOSOME COMPOSITIONS | Merrimack Pharmaceuticals, Inc. (US) | 2019-01-23 | — | — | EP | disclosed |
| US-20180021294-A1 | Ephrin Receptor A2 (EPHA2)-Targeted Docetaxel-Generating Nano-Liposome Compositions | MERRIMACK PHARMACEUTICALS, INC. | 2018-01-25 | — | — | US | disclosed |
| WO-2017161067-A1 | EPHRIN RECEPTOR A2 (EPHA2)-TARGETED DOCETAXEL-GENERATING NANO-LIPOSOME COMPOSITIONS | MERRIMACK PHARMACEUTICALS, INC (US) | 2017-09-21 | — | — | WO | disclosed |
| WO-2017161071-A1 | TREATING EPHRIN RECEPTOR A2 (EPHA2) POSITIVE CANCER WITH TARGETED DOCETAXEL-GENERATING NANO-LIPOSOME COMPOSITIONS | MERRIMACK PHARMACEUTICALS, INC (US) | 2017-09-21 | — | — | WO | disclosed |
| US-5500334-A | Silver halide color photographic material containing pyrazole-substituted couplers | FUJI PHOTO FILM CO., LTD. (JP) | 1996-03-19 | — | — | US | disclosed |
| US-5498419-A | SIDE EFFECT REDUCTION | PARS HARRY G (US) | 1996-03-12 | — | — | US | disclosed |
| WO-1995033429-A1 | FUMARATE SALT OF 4-(DIETHYL-3-(1-METHYLOCTYL)- 7, 8, 9, 10-TETRAHYDRO-6, 6, 9-TRIMETHYL-6H-DIBENZO[B, D]PYRAN-1-OL, 4-(DIETHYL-AMINO)BUTYRIC ACID ESTER | PARS HARRY G (US) | 1995-12-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190070113-A1 | Treating Ephrin Receptor A2 (Epha2) Positive Cancer with Targeted Docetaxel-Generating Nano-Liposome Compositions | EPHA2, EPHB2, EPHB1 | LMNA 4076/4885CYP3A4 4494/4885MAPT 3112/4885 |
| US-20180021294-A1 | Ephrin Receptor A2 (EPHA2)-Targeted Docetaxel-Generating Nano-Liposome Compositions | EPHA2, EPHB2, EPHB1 | LMNA 2969/4885CYP3A4 3810/4885MAPT 1871/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.